Epizyme Inc (EPZM) Given Consensus Recommendation of “Buy” by Brokerages

Epizyme Inc (NASDAQ:EPZM) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $23.10.

A number of equities research analysts have commented on EPZM shares. ValuEngine downgraded Epizyme from a “sell” rating to a “strong sell” rating in a research report on Monday, April 9th. Wedbush restated an “outperform” rating and issued a $25.00 target price (down previously from $26.00) on shares of Epizyme in a research report on Wednesday, March 14th. BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. Leerink Swann lifted their target price on Epizyme from $22.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Thursday, March 15th.

Several hedge funds and other institutional investors have recently modified their holdings of EPZM. Schwab Charles Investment Management Inc. grew its stake in shares of Epizyme by 13.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 245,756 shares of the biopharmaceutical company’s stock valued at $3,085,000 after buying an additional 28,588 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Epizyme in the fourth quarter valued at $202,000. Bailard Inc. acquired a new stake in shares of Epizyme in the fourth quarter valued at $251,000. The Manufacturers Life Insurance Company grew its stake in shares of Epizyme by 18.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 38,451 shares of the biopharmaceutical company’s stock valued at $482,000 after buying an additional 6,005 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Epizyme by 5.3% in the fourth quarter. Bank of New York Mellon Corp now owns 212,983 shares of the biopharmaceutical company’s stock valued at $2,672,000 after buying an additional 10,805 shares in the last quarter. 85.22% of the stock is owned by institutional investors and hedge funds.



NASDAQ:EPZM opened at $14.85 on Tuesday. Epizyme has a 52 week low of $11.15 and a 52 week high of $21.40. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.81 and a beta of 2.09.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.05. During the same period in the previous year, the company posted ($0.56) earnings per share. equities research analysts expect that Epizyme will post -2.22 EPS for the current fiscal year.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply